The German sleep-wake disorder market is estimated to grow at a CAGR of 6.2% during the forecast period. Germany is the major contributor to the healthcare sector in Europe. The factors such as the increasing prevalence of behavioral health disorders, considerable resources of mental health, and a sophisticated healthcare system are the key factors that are expected to promote the growth of the market in the near future. As per WHO, the government’s total expenditure on mental health was 11.27% of the total government health expenditure in 2017. Additionally, total mental health expenditure per person was around $392 in 2017.
To Request a Sample of our Report on German Sleep-Wake Disorder Market: https://www.omrglobal.com/request-sample/german-sleep-wake-disorder-market
The market is segmented on the basis of type and treatment. Based on type, the market is sub-segmented into insomnia, hypersomnia, sleep apnea, circadian rhythm disorders, and others. Sleep apnea holds the largest market share during the forecast period. On the basis of treatment, the market is divide into therapies, drugs, and devices. The sleep-wake disorder devices segment is estimated to hold the largest market share during the forecast period, followed by medications. Some of the players operating in the market include Koninklijke Philips N.V, Medtronic PLC, Sanofi SA, Jazz Pharmaceutical Inc., and others.
In January 2020, Jazz Pharmaceuticals, SK Biopharmaceutical’s US partner received sales approval from the European Medicine Agency (EMA) for Sunosi (Ingredient: solriamfetol), a treatment for improving wakefulness in patients suffering from excessive daytime sleepiness related with narcolepsy or obstructive sleep apnea. SK Biopharmaceutical discovered Sunosi and completed its phase 1 clinical trial before licensing out the substance to Aerial BioPharma in 2011. Thereafter, Jazz Pharmaceuticals took over the global commercialization rights, including the US and Europe, for completing the phase 3 clinical trials for the drug. With this approval, Jazz Pharma has planned to launch Sunosi in Germany in mid-2020 and then to France and UK by early 2021.
(Get 15% Discount on Buying this Report)
A full Report of German Sleep-Wake Disorder Market is Available at: https://www.omrglobal.com/report-customization/german-sleep-wake-disorder-market
German Sleep-Wake Disorder Market Segmentation
By Type
· Insomnia
· Hypersomnia
· Circadian Rhythm Disorders
· Others
By Treatment
· Therapies
· Drugs
· Devices
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
